CNS volume 13 issue 12 Cover and Front matter

Brief Summary: Consult the package insert for complete prescribing information.WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.Anyone considering the use of Cymbalta or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.Short-term studies did not show an increase age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide.Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.Families and caregivers should be advised of the need for close observation and communication with the prescriber.Cymbalta is not approved for use in pediatric patients.[See Warnings and INDICATIONS AND USAGE: Major Depressive Disorder-Cymbalta is indicated for the acute and maintenance treatment of major depressive disorder (MDD). Generalized Anxiety Disorder-Cymbalta is indicated for the acute treatment of generalized anxiety disorder (GAD).Diabetic Peripheral Neuropathic Pain-Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy.Fibromyalgia-Cymbalta is indicated for the management of fibromyalgia (FM).CONTRAINDICATIONS: Monoamine Oxidase Inhibitors-Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serious, sometimes fatal, drug interactions with serotonergic drugs.These interactions may include hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.These reactions have also been reported in patients who have recently discontinued serotonin reuptake inhibitors and are then started on an MAOI.Some cases presented with features resembling neuroleptic malignant syndrome [see Warnings and Precautions].Uncontrolled Narrow-Angle Glaucoma-In clinical trials, Cymbalta use was associated with an increased risk of mydriasis; therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma [see Warnings and Precautions].WARNINGS AND PRECAUTIONS: Clinical Worsening and Suicide Risk-Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders.Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients.The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD.The risk of differences (drug vs placebo), however, were relatively stable within age strata and across indications.These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.